Positioning political buying, disclosed 2026-08-31
Options no verdict drawn today, left as found
Ethical passes the values gate
Price54.17 USD
Fair value92.00
Ethical score90.4/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-09-02Read Markdown75.80-28.5% to today ✓
2026-08-25Read Accumulation75.80-28.5% to today
2026-07-25Read Markup71.71-24.5% to today
2026-07-18Read Markdown67.34-19.6% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cooper Companies (The) holds its Distribution at $54.17. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-09-10
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$54.17
Valuation
18.62 trailing · 11.34 forward price to earnings
Values screen
PASS· score 90.4
Beta
0.82
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
20.21%
Below 33%
Interest-bearing debt is just 20.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
7.58%
Below 49%
Money owed to the company is 7.6% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 70% discount to our $92.00 fair value, narrow competitive moat, 7.90% revenue growth.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. A 69.8% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +57% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Contact Lenses Meet a Clear Margin of Safety
Millions slip on contact lenses each morning without a second thought about who makes them. Cooper Companies supplies a big slice of that market through its CooperVision division, with a smaller surgical side that adds steady demand.
The shares sit at $71.71 against our $92 fair value, a 28% margin of safety on 8% revenue growth and a 14.3 times forward earnings multiple. The business clears the ethical screen without issues and carries a narrow but real competitive edge.
Low returns on equity at 3% and slim 6% profit margins leave little cushion if rivals push harder or volumes slow. The narrow moat means any slip shows up quickly in results.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
COO trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-09Markdown$75.80+0.0%Entry 12
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-08Markdown$75.80+0.0%Entry 11
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-06Markdown$75.80+0.0%Entry 10
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-05Markdown$75.80+0.0%Entry 9
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-04Markdown$75.80+0.0%Entry 8
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-03Markdown$75.80+0.0%Entry 7
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-02Markdown · changed$75.80+0.0%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.7% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91.
2026-07-25Markup · changed$71.71+6.5%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91.
2026-07-18Markdown$67.34+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (15 analysts) rates it none, with a mean price target of $91.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
